IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses
This study has been completed.
Sponsor:
Derm Research @ 888 Inc.
Collaborator:
3M
Information provided by:
Derm Research @ 888 Inc.
ClinicalTrials.gov Identifier:
NCT00110682
First received: May 12, 2005
Last updated: April 21, 2008
Last verified: April 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study Aims:
- To compare the long-term efficacy and safety of imiquimod versus vehicle used as an adjunct to cryotherapy.
- To assess and compare the recurrence rate and time to recurrence of the 2 different treatment groups.
Hypothesis: The imiquimod arm will produce a more prolonged clearing of Actinic Keratoses (AK) compared to the vehicle arm.
| Condition | Intervention | Phase |
|---|---|---|
| Keratosis Actinic Keratosis | Drug: Imiquimod used as an adjunct to cryotherapy | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment |
| Official Title: | A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up |
Resource links provided by NLM:
Further study details as provided by Derm Research @ 888 Inc.:
Primary Outcome Measures:
- Recurrence rate and time to recurrence of lesions
Secondary Outcome Measures:
- Time to reach treatment success
- Percentage of patients who clear
- Patient improvement assessment
| Estimated Enrollment: | 60 |
| Study Start Date: | April 2005 |
| Study Completion Date: | December 2006 |
| Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
Evaluation of: (i) topical imiquimod 5% cream or (ii) vehicle cream used two times weekly for eight weeks starting two weeks post cryotherapy.
Study Aims:
- To assess and compare the recurrence rate and time to recurrence of the 2 different treatment groups.
- To assess and compare the efficacy of the 2 different treatment groups.
- To assess and compare the safety of the 2 different treatment groups.
Study Design: 6 visits over 62 weeks
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of actinic keratosis with 4 or more discreet lesions on the face or balding scalp. Lesions must be within a treatment area not exceeding 50 cm2 (combined total must not exceed 50 cm2)
- Women of childbearing potential using appropriate contraceptive methods
Exclusion Criteria:
- Previous treatments with imiquimod for AK in the prescribed area within the past 5 months or cryosurgery in the same area within the past 4 weeks.
- Patients unwilling to stay out of the sun or wear protective clothing or to use sunscreen with a minimum of SPF 15 during the study.
- Basal or squamous cell carcinomas in the prescribed treatment area in the past 2 years.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00110682
Please refer to this study by its ClinicalTrials.gov identifier: NCT00110682
Locations
| Canada, British Columbia | |
| DermResearch @ 888 Inc | |
| Vancouver, British Columbia, Canada, V4C 6X4 | |
| Canada, Ontario | |
| Windsor Clinical Research | |
| Windsor, Ontario, Canada | |
| Canada, Quebec | |
| Centre de Recherche Dermatologique, CRDQ | |
| Sainte-Foy, Quebec, Canada, G1V 4X7 | |
Sponsors and Collaborators
Derm Research @ 888 Inc.
3M
Investigators
| Principal Investigator: | Yves Poulin, MD FRCPC | Centre de Recherche Dermatologique du Quebec Metropolitaine |
| Principal Investigator: | Jerry KL Tan, MD FDRPC | U. of Western Ontario, Windsor Ontario |
| Principal Investigator: | Richard Thomas, MD FRCPC | Derm Research @ 888 Inc. |
More Information
| Responsible Party: | D Richard Thomas, Department of Dermatology and Skin Science |
| ClinicalTrials.gov Identifier: | NCT00110682 History of Changes |
| Other Study ID Numbers: |
DR 2004-05 |
| Study First Received: | May 12, 2005 |
| Last Updated: | April 21, 2008 |
Keywords provided by Derm Research @ 888 Inc.:
|
Actinic Keratosis Cryotherapy Imiquimod |
Additional relevant MeSH terms:
|
Keratosis Keratosis, Actinic Skin Diseases Precancerous Conditions Neoplasms Imiquimod |
Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Interferon Inducers |
ClinicalTrials.gov processed this record on August 17, 2017